摘要
目的评价选择性五羟色胺再摄取抑制剂(SSRIs)舍曲林对冠心病合并抑郁患者的死亡率、心肌梗死(以下简称心梗)再发率、射血分数、心率变异性(SDNN、RMSSD、LF/HF、Ln LF、Ln HF)的影响。方法计算机检索Medline、Web of Sci-ence、Pub med、Cochtane Central Register of Controlled Trials(CENTRAL)、中国生物医学文献数据库、中国期刊全文数据库中关于冠心病、心肌梗死、抑郁和SSRIs舍曲林的随机对照试验,同时筛检纳入文献的的参考文献。对文献质量进行严格评价和资料提取,对符合质量标准的随机对照试验(RCT)进行系统评价(Meta)分析。结果检索到11篇相关文献,其中英文7篇,中文4篇。研究表明舍曲林对冠心病合并抑郁患者的死亡率OR值为0.56(95%CI为0.42~0.75,P<0.01)、再发心肌梗死率OR为0.72(95%CI为0.52~0.98,P<0.05),射血分数的加权均数差为3.43(95%CI为0.46~6.41,P<0.05),LnHF的加权均数差为-0.21(95%CI为-0.39^-0.03,P<0.05),与安慰剂相比有显著差别。结论冠心病合并抑郁患者服用SSRIs舍曲林有积极的治疗作用。
[Objective]To evaluate the effect of selective serotonin reuptake inhibitors（SSRIs） Sertraline on the mortality,myocardial infarction recurrence rate,ejection fraction,heart rate variability（SDNN,RMSSD,LF/HF,Da II,Ln HF） of patients with coronary heart disease and depression.[Methods]The randomized controlled trials（RCT） about coronary heart disease,myocardial infarction,depression,and SSRIs Sertraline were searched in Medline,Web of Science,Pub med,Cochtane Central Register of Controlled Trials（CENTRAL）,China biological medical literature database,CNKI.Meanwhile,the references of the selected literatures were also screened.After rigorous assessment and data extraction,Meta-analysis was performed on the qualified RCTs.[Results]A total of 11 literatures were selected,including 7 English ones and 4 Chinese ones.The study showed Sertraline was significantly superior to placebo for decreasing mortality OR 0.56（95%CI 0.42~0.75,P0.01） and recurrence rate of myocardial infarction OR 0.72（95%CI 0.52~0.98,P0.05）.Sertraline was significantly superior to placebo for increasing ejection fraction weighted mean difference by 3.43（95%CI 0.52~0.98,P0.05） and Ln HF weighted mean difference by-0.21（95%CI-0.39^-0.03,P0.05）[Conclusion]Treatment with Sertraline for coronary heart disease with depression results in significant therapeutic effects.
出处
《职业与健康》
CAS
2011年第18期2060-2064,共5页
Occupation and Health
关键词
冠心病
抑郁
SSRIS
舍曲林
Coronary Heart Disease
Depression
SSRIs
Sertraline
